Literature DB >> 32919997

Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab.

Rona Z Silkiss1, Michael K Paap2, Kelsey A Roelofs3, Jorge Agi4, Ezekiel Weis5.   

Abstract

Entities:  

Year:  2020        PMID： 32919997     DOI： 10.1016/j.jcjo.2020.07.020

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN： 0008-4182            Impact factor:   1.882


× No keyword cloud information.
  5 in total

1.  Thyroid Eye Disease.

Authors:  Jason Szelog; Hollister Swanson; Matthew C Sniegowski; David B Lyon
Journal:  Mo Med       Date:  2022 Jul-Aug

Review 2.  2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease.

Authors:  Thanh D Hoang; Derek J Stocker; Eva L Chou; Henry B Burch
Journal:  Endocrinol Metab Clin North Am       Date:  2022-05-11       Impact factor: 4.748

3.  A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease.

Authors:  Myra B Safo; Rona Z Silkiss
Journal:  Am J Ophthalmol Case Rep       Date:  2021-03-10

4.  Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers.

Authors:  Shanlee M Stevens; Nathan Pirakitikulr; Bradford W Lee
Journal:  Taiwan J Ophthalmol       Date:  2022-02-28

Review 5.  Ocular Drug Delivery: Advancements and Innovations.

Authors:  Bo Tian; Evan Bilsbury; Sean Doherty; Sean Teebagy; Emma Wood; Wenqi Su; Guangping Gao; Haijiang Lin
Journal:  Pharmaceutics       Date:  2022-09-13       Impact factor: 6.525
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.